Phase Holographic Imaging logotype

Investor Relations

Welcome to the Investor Relations for Phase Holographic Imaging (PHI)

What’s New

About PHI

Phase Holographic Imaging (PHI) develops and markets its non-invasive time-lapse imaging instruments. The company’s current HoloMonitor® products are globally used for long-term quantitative analysis of living cell cultures, particularly in preclinical research.

Now, PHI is actively focusing on business development. With unique solutions focused on Quantitative Phase Imaging (QPI) — a technology that brings a novel, cell-friendly approach to critical cell quality evaluation, PHI is expanding into the fast-growing regenerative medicine field.

PHI envisions transforming live cell analysis and establishing its QPI technology as a standard for cell quality control, making our future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.

July 2024 Interview with PHI AB — Step inside our headquarters and meet the team!

Finwire Media interviewed us about our current business and future outlook in regenerative medicine. How are we shaping the future of scientific research and cell therapy quality control with our innovative live cell analysis technology? How are we positioned to reach profitability, and why do investors take a closer look at PHI?

Investor Information

report banner investor relations

All Press Releases

Here you can read all PHI press releases.

A fluorescence equipped HoloMonitor system operating inside a cell incubator at Novo Nordisk A/S

Company News

Here you see PHI featured in news and CEO commentaries.

graph banner

Reports & Documents

Here you find PHI’s interim and annual reports, as well as view general meeting and emission documents.

question banner investor relations phase holographic imaging

Investor Q&A

Here you can browse the frequently asked investor questions and quickly find your answers.

Any questions? Please get in touch with our CEO,
Patrik Eschricht, at:

Investor Calendar

August 19, 2024 at 14:00

September 16, 2024

End of September

Stock Information

The PHI stock is listed on the Spotlight Stock Market,
a Multilateral Trading Facility (MTF).

PHI is pursuing a dual listing on the US-based OTCQB Venture Market. Read the Press release (July 8, 2024).

Subscribe to the latest PHI news from BioStock, Kalqyl and Cision to stay informed.
You are welcome to follow PHI on social media, where we keep in touch with our global HoloMonitor community.

On behalf of PHI, I want to thank our investor community for sharing our vision, and believing in the company and the impact our products and technology have on advancing research within life science and the future of medicine.